Brief: Lisata Therapeutics' Cancer Drug Gets US FDA Orphan Drug Designation
09/04/2024 13:41
April 9 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS ANNOUNCES U.S. FDA ORPHAN DRUG
DESIGNATION
GRANTED TO LSTA1 FOR THE TREATMENT OF OSTEOSARCOMA
Source text for Eikon: ID:nGNX1Hd561
Further company coverage: LSTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Lisata Therapeutics Announces New Method Of Use Patent Granted For Certepetide In The Treatment Of Pancreatic Cancer And Other Solid Tumors
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE -Expeditors International, Waters, Ameresco